Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

References

• SeeleyDGBrownerWSNevittMCWhich fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research GroupAnn Intern Med19911158378421952469
   PubMed Web of Science ®Google Scholar
• DelmasPDVan deLLWattsNBUnderdiagnosis of vertebral fractures is a worldwide problem: the IMPACT studyJ Bone Miner Res20052055756315765173
   PubMed Web of Science ®Google Scholar
• DelmasPDVan deLLWattsNBMortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS)Osteoporos Int199882912979797915
   PubMed Web of Science ®Google Scholar
• LindsayRSilvermanSLCooperCRisk of new vertebral fracture in the year following a fractureJAMA200128532032311176842
   PubMed Web of Science ®Google Scholar
• LindsayRBurgeRTStraussDMOne year outcomes and costs following a vertebral fractureOsteoporos Int20041788515167988
   PubMed Web of Science ®Google Scholar
• MeltonLI3rdTherneauTMLarsonDRLong-term trends in hip fracture incidence and survivalOsteoporos Int1998868749692080
   PubMed Web of Science ®Google Scholar
• GullbergBJohnellOKanisJAWorld-wide projections for hip fractureOsteoporos Int199774074139425497
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomized trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention Trial Research GroupLancet1996348153515418950879
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Trial (VERT) Study GroupJAMA19992821344135210527181
   PubMed Web of Science ®Google Scholar
• ChestnutCHIIISkagAChristiansenCEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res2004191241124915231010
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce yearly zolendronic acid for treatment of postmenopausal osteoporosisN Engl J Med20073561809182217476007
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDEffect of risedronate on the risk of hip fracture in elderly women. HIP Intervention Program Study GroupN Engl J Med200134433334011172164
   PubMed Web of Science ®Google Scholar
• RussellRGGDeterminants of structure-function relationships among bisphosphonatesBone200740Suppl 2521525
   Google Scholar
• Van BeckELowikCQueIDissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl group with an amino groupJ Bone Miner Res199611149214978889849
   PubMed Web of Science ®Google Scholar
• EbetinoFHFrancisMDRogersMJMechanisms of action of etidronate and other bisphosphonatesRev Contemp Pharm19989233243
   Google Scholar
• LuckmanSPHughesDECoxonFPNitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP binding proteins, including RASJ Bone Miner Res1998135815899556058
   PubMed Web of Science ®Google Scholar
• RouxCSeemanEEastelREfficacy of risedronate on clinical vertebral fractures within six monthsCurr Med Res Opin20042043343915119979
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone20063861762716046206
   PubMed Web of Science ®Google Scholar
• WattsNBWorleyKSolisAComparison of risedronate and alendronate relative to calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims databaseJ Manag Care Pharm20041014215115032563
   PubMedGoogle Scholar
• SilvermanSLWattsNBDelmasPDEffectiveness of bisphosphonates on nonvertebral fracture and hip fractures in the first year of therapy: the risedronate and etidronate (REAL) cohortOsteoporos Int200718253417106785
   PubMed Web of Science ®Google Scholar
• CharpurlatRDDelmasPDDrug insight: bisphosphonates for postmenopausal osteoporosisNat Clin Pract Endocrinol Metab2006221121916932286
   PubMedGoogle Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int200011839110663363
   PubMed Web of Science ®Google Scholar
• MellstromDDSorensenOHGoemaSSeven years of treatment with risedronate in women with postmenopausal osteoporosisCalcif Tissue Int20047546246815455188
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc2006811013102216901023
   PubMed Web of Science ®Google Scholar
• LombasCHakimCZanchettaJRCompliance with alendronate treatment in an osteoporosis clinicJ Bone Miner Res200115S529
   Web of Science ®Google Scholar
• BrownJPKendlerDLMcClungMRThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int20027110311112085156
   PubMed Web of Science ®Google Scholar
• DelmasPDBenhamouCLManZMonthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsOsteoporos Int2008191039104518087660
   PubMed Web of Science ®Google Scholar
• DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone200842364217920005
   PubMed Web of Science ®Google Scholar
• WellsGCranneyAPetersenJRisedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database Syst Rev200823CD 004523
   Google Scholar
• PeerGYJacobsenSJMeltonLJMortality following hip fractureFacts Res Gerontol1994791109
   Google Scholar
• RivadeneiraFZillikensMCDe LaetCEFemoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam StudyJ Bone Miner Res2007221781179017638578
   PubMed Web of Science ®Google Scholar
• RingeJDFaberHFarahmandPEfficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1 year studyRheumatol Int20062642743116001181
   PubMed Web of Science ®Google Scholar
• WallachSCohenSReidDMEffects if risedronate on bone density and vertebral fracture in patients on corticosteroid therapyCalcif Tissue Int20006727728511000340
   PubMed Web of Science ®Google Scholar
• SatoYIwamotoJKanokoTRisedronate sodium therapy for prevention of hip fracture in men 65 years or older after strokeArch Intern Med20051651743174816087822
   PubMed Web of Science ®Google Scholar
• SatoYIwamotoJKanokoTRisedronate therapy for prevention of hip fracture after stroke in elderly womenNeurology20056481181615753414
   PubMed Web of Science ®Google Scholar
• SatoYKanokoTSatohKThe prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trialArch Intern Med20051651737174216087821
   PubMedGoogle Scholar
• SatoYHondaYIwamotoJRisedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson diseaseNeurology20076891191517372126
   PubMed Web of Science ®Google Scholar
• TaggartHBologneseMALindsayRUpper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trialsMayo Clin Proc20027726227011888030
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBLiZTwo year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosisCurr Med Res Opin20042075776415140343
   PubMed Web of Science ®Google Scholar
• PazianisMMillerPBlumentalsWAA review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristicsClin Ther2007291548155817919538
   PubMed Web of Science ®Google Scholar
• EtminanMAminzadehKMatthewIRUse of oral bisphosphonates and the risk of aseptic necrosis: a nested case-control studyJ Rheumatol20083569169518203310
   PubMed Web of Science ®Google Scholar
• MarxRECilloJEJrUlloaJJOral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatmentJ Oral Maxillofac Surg2007652397241018022461
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJAmerican Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2007221479149117663640
   PubMed Web of Science ®Google Scholar
• American Dental Association Council on Scientific AffairsExpert panel recommendations: Dental management of patients receiving oral bisphosphonate therapyJ Am Dent Assoc20061371144115016873332
   PubMed Web of Science ®Google Scholar
• MillerPDRouxCBoonenSSafety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trialsJ Bone Miner Res2005202105211516294264
   PubMed Web of Science ®Google Scholar
• FraunfelderFWFraunfelderFTBisphosphonates and ocular inflammationN Engl J Med20033481187118812646685
   PubMed Web of Science ®Google Scholar
• StrampelWEmkeyRCivitelliRSafety considerations with bisphosphonates for the treatment of osteoporosisDrug Saf20073075576317722968
   PubMed Web of Science ®Google Scholar